arrow
R

Richard E. Pratley

AdventHealth
H指数:121
被引数:6.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

Apitegromab在tirzepatide诱导的体重减轻期间用于瘦肉保存: 一项随机,双盲,安慰剂对照的2期试验

2026-06-080
OAAI
Associations between dietary patterns and diabetes in patients with acute pancreatitis: a cross-sectional analysis from the DREAM study

饮食模式与急性胰腺炎患者糖尿病之间的关联:DREAM研究的横断面分析

2026-03-270
OAAI
Preparing to Meet the Needs of a Growing Older Adult Population with Type 1 Diabetes: A Narrative Review

为满足日益增长的1型糖尿病老年人群的需求做准备:一项叙事综述

2025-12-080
PRE
Dietary Patterns for Weight and Glycemic Management in Persons With Type 1 Diabetes: A Meta-analysis of Clinical Trials

Igudesman, D.; Nally, L.M.; Grimshaw, A.A.; Gunderson, C.; Considine, E.G.; Jacobsen, L.M.; Tosur, M.; Gottlieb, P.A.; Hirsch, I.; Laffel, L.; 等. 1型糖尿病患者的体重与血糖管理饮食模式:一项临床试验的Meta分析. J. Clin. Endocrinol. Metab. 2025, 110, 3289–3300. [Google Scholar] [CrossRef]

2025-08-012
OA
Research Gaps; Challenges; and Opportunities in Automated Insulin Delivery Systems*

自动化胰岛素递送系统的研究空白、挑战与机遇*

2025-07-010
PRE
Research Gaps, Challenges, and Opportunities in Automated Insulin Delivery Systems

自动化胰岛素输注系统中的研究空白、挑战与机遇

2025-07-010
PRE
Automated Insulin Delivery in Elderly with Type 1 Diabetes: A Prespecified Analysis of the Extension Phase
2025-03-010
PRE
Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor Agonists Alone and in Combination With SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

GLP-1受体激动剂单独或联合SGLT2抑制剂治疗2型糖尿病的心血管、肾脏和安全性结局: 系统评价和荟萃分析

2024-11-261
OA
Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist, at 4 x 450 μg Doses Reduces Blood Pressure, Lipids, and Body Weight in Post-menopausal Females: A Phase I Study

每周一次注射的Utreglutide(GL0034),一种胰高血糖素样肽-1受体激动剂,在4×450 μg剂量的情况下,可降低绝经后女性的血压、血脂和体重:一项I期研究

2024-11-120
PRE